Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 24448 in Major Depressive Disorder
NCT00113022Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- May 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of farampator in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started May 2005; status: terminated.
02
Drugs
farampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00113022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113022.